PMID- 18461337
OWN - NLM
STAT- MEDLINE
DCOM- 20090113
LR  - 20211020
IS  - 0179-1958 (Print)
IS  - 0179-1958 (Linking)
VI  - 23
IP  - 8
DP  - 2008 Aug
TI  - HLA-A2 expression, stage, and survival in colorectal cancer.
PG  - 767-72
LID - 10.1007/s00384-008-0488-y [doi]
AB  - INTRODUCTION: Most cancer vaccination trials have been performed in human 
      leukocyte antigen (HLA)-A2 positive populations. Some studies have used HLA-A2 
      negative patients as control group. However, HLA-type and HLA-expression can 
      interact with tumor biology and possibly affect prognosis. HLA-A2 negative 
      patients might constitute an inadequate control group. MATERIALS AND METHODS: 
      Patients with colorectal cancer were serologically analyzed for HLA-A2 
      expression. Patients were evaluated for tumor stage, grading, tumor location. 
      Overall survival (OAS) of HLA-A2 positive and HLA-A2 negative patients was 
      compared. RESULTS: One hundred forty-four patients were evaluable (50% HLA-A2+). 
      Median age was 62 years. UICC stage III or IV: 45.8%. Gender, location, and UICC 
      stage were equally distributed between HLA-A2 subgroups. HLA-A2 positive patients 
      more frequently had grade 3 histology (27.8% vs 13.9%) and chemotherapy (62.9% vs 
      45.6%). At a median follow-up of 75.8 months, median OAS for the entire study 
      population was 123.3 months, 5-year OAS was 77.5%. No statistically significant 
      difference in OAS was observed between HLA-A2 positive and negative patients 
      (116.5 vs 157 months, 5-year-OAS 74.1+/-11.6% vs 81+/-11.6%, p=0.46). Expectedly, 
      patients with UICC stage I and II disease lived significantly longer than 
      patients with stage III and IV (5-year OAS 94.3% vs 53.4%; p<0.001). A 
      significantly superior OAS was also found for women, independent of stage or HLA 
      status. CONCLUSION: HLA-A2 positive patients exhibit poorer tumor 
      differentiation. This might account for a non-significant difference in OAS. The 
      use of HLA-A2 negative patients as control cohort in CRC vaccinations would 
      rather underestimate potential treatment-related survival effects. Therefore, we 
      suggest they constitute a valid auxiliary control group.
FAU - Kiewe, Philipp
AU  - Kiewe P
AD  - Department of Hematology and Oncology, Charite-Universitatsmedizin Berlin, Campus 
      Benjamin Franklin, Hindenburgdamm 30, 12200, Berlin, Germany.
FAU - Mansmann, Veit
AU  - Mansmann V
FAU - Scheibenbogen, Carmen
AU  - Scheibenbogen C
FAU - Buhr, Heinz-Johannes
AU  - Buhr HJ
FAU - Thiel, Eckhard
AU  - Thiel E
FAU - Nagorsen, Dirk
AU  - Nagorsen D
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20080507
PL  - Germany
TA  - Int J Colorectal Dis
JT  - International journal of colorectal disease
JID - 8607899
RN  - 0 (Antineoplastic Agents)
RN  - 0 (HLA-A2 Antigen)
SB  - IM
MH  - Adult
MH  - Antineoplastic Agents/therapeutic use
MH  - Colorectal Neoplasms/*metabolism/*mortality/pathology/therapy
MH  - Drug Utilization
MH  - Female
MH  - Follow-Up Studies
MH  - HLA-A2 Antigen/*metabolism
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Prognosis
MH  - Sex Factors
MH  - Survival Analysis
EDAT- 2008/05/08 09:00
MHDA- 2009/01/14 09:00
CRDT- 2008/05/08 09:00
PHST- 2008/04/02 00:00 [accepted]
PHST- 2008/05/08 09:00 [pubmed]
PHST- 2009/01/14 09:00 [medline]
PHST- 2008/05/08 09:00 [entrez]
AID - 10.1007/s00384-008-0488-y [doi]
PST - ppublish
SO  - Int J Colorectal Dis. 2008 Aug;23(8):767-72. doi: 10.1007/s00384-008-0488-y. Epub 
      2008 May 7.